Clinical features and prognostic factors in papillary thyroid microcarcinoma depends on age

Jin-Kyu CHO; Ju-Yeon KIM; Chi-Young JEONG; Eun-Jung JUNG; Soon-Tae PARK; Sang-Ho JEONG; Young-Tae JU; Young-Joon LEE; Soon-Chan HONG; Woo-Song HA; Sang-Kyung CHOI.
Journal of the Korean Surgical Society ; : 281-287, 2012.
Artículo en Inglés | WPRIM | ID: wpr-111457

Documentos relacionados

  1. Effect of prepropeptide replacement on γ-carboxylation and activity of recombinant coagulation factor IX.
  2. FIX It in One Go: Enhanced Factor IX Gene Therapy for Hemophilia B.
  3. How to fix the NHS.
  4. Plasma factor IX: The tip of the iceberg?
  5. Thromboinflammatory effects of RBC microvesicles.
  6. Revised terminal half-life of nonacog alfa as derived from extended sampling data: A real-world study involving 64 haemophilia B patients on nonacog alfa regular prophylaxis.
  7. A new population pharmacokinetic model for recombinant factor IX-Fc fusion concentrate including young children with haemophilia B.
  8. Correlation of antigen expression with epigenetic modifications after rAAV delivery of a human factor IX variant in mice and rhesus macaques.
  9. Impact of formaldehyde, acetaldehyde, and N-(3-(Dimethylamino)propyl)methacrylamide on the efficacy of the human derived coagulation factor IX.
  10. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.